ASGCT 24th Annual Meeting

DATE

Tuesday, May 11, 2021 - Friday, May 14, 2021

LOCATION

Virtual

Attendee at ASGCT 24th Annual Meeting

Join us at the American Society of Cell and Gene Therapy’s (ASCGT) virtual 24th Annual Meeting for four days of informative presentations to help advance the knowledge, awareness, and education leading to the development of cell and gene therapies. You’ll have the opportunity to network with fellow peers in the industry, including scientists, physicians, and patient advocates, about the latest happenings in this ever-changing field.

As part of the event, we will be part of an industry-sponsored symposium "Accelerating and Achieving Your Cell Therapy Program Goals: 
A Focus on CAR T Development" on Thursday, May 13th, 2 - 3:30 pm EST. 

The Importance of Starting Material for Cell Therapies – Your CAR Depends on It

Presented by Dominic Clarke, PhD, Director Global Cell Therapy Strategy & Innovation, HemaCare at Charles River Laboratories
20 min presentation; 5 minute Q&A (Moderator: Shawna Jackman)

CAR-T Binder Discovery Simplified: Any Target, 50 Antibodies. Engineered Specifically for CAR Formats

Presented by Giles Day, Site Director, Distributed Bio at Charles River Laboratories
15 min presentation; 5 minute Q&A (Moderator: Shawna Jackman)

In Vitro Efficacy and Safety Testing of Your Cellular Therapy – A Good CAR Inspection

Presented by Sabrina de Munnik, PhD, Senior Scientist, Biology, Charles River Laboratories
15 min presentation; 5 minute Q&A (Moderator: Shawna Jackman)
Take Your CAR and Drive It – Charting Your Path to Market
Presented by Steven Miklasz, Advanced Therapy & Key Accounts Development Director, Charles River Laboratories
20 min presentation; 5 minute Q&A (Moderator: Shawna Jackman)

Featured Speakers

 

Dominic Clarke Headshot

Dominic Clarke, PhD
Global Head of Cell Therapy
HemaCare at Charles River Laboratories

 

Dr. Clarke is currently the Global Head of Cell Therapy at HemaCare, a leading provider of source material for clinical development and commercial manufacturing of cell-based therapies. He previously worked at Charter Medical and BioLife Solutions.

Dominic has a PhD in cellular and molecular biology from Binghamton University and did post-doctoral work in cell and developmental biology at State University of New York Upstate Medical University. He is the current co-chair for the International Society for Cell and Gene Therapies Process and Product Development Committee.


Sabrina de Munnik Headshot

Sabrina de Munnik, PhD
Senior Scientist, Biology
Charles River Laboratories

 

Dr. de Munnik is Senior Scientist at Charles River Laboratories in Leiden, The Netherlands. Her research focuses on efficacy and toxicity testing of novel drug therapies in human primary cell based models. Dr. de Munnik has a broad background in molecular and cellular biology. She holds a PhD in receptor pharmacology from the VU University in Amsterdam, The Netherlands.


Steven Miklasz Headshot

Steven Miklasz, MSc, CBA
Advanced Therapy & Key Accounts Development Director
Charles River Laboratories

 

Steven is the Advanced Therapy and Key Account Development Director for Charles River Biologics Testing Solutions division. He is a subject matter expert for CMC for Biologics, and more recently for cell and gene therapy products. Mr. Miklasz provides guidance and support for our CGMP portfolio services directed towards expansion of new services in areas of unmet need for advanced therapies, often deriving insights from scientific client consultation, attendance at professional meetings, and close monitoring of market trends.


Giles Day Headshot

Giles Day
Site Director, Antibody Discovery South San Francisco
Distributed Bio at Charles River Laboratories

 

Giles graduated from the University of Manchester with BSc in Biology and MSc in Bioinformatics. From there he joined Pfizer in the UK establishing Bioinformatics as a core discipline within the drug discovery programs.

Over the next 15 years Giles held numerous leadership postions in the Pfizer informatics organization. His teams developed ground-breaking solutions for HTS, med chem and target identification. In 2007 Pfizer created a new R&D division, the Biotechnology and Bioinnovation Center (BBC) in San Francisco. Giles was appointed head of informatics for the division leading a global team that supported all aspects of the BBC, from Prof. Goodmans Blackberry to running protein-protein docking at Amazon and supporting clinical trials.

Following the Wyeth merger and disbanding of the BBC, Giles, Jake and Chris decided that this was the ideal time to create Distributed Bio and bring their wealth of experience to new partners. Chris and Giles formed Distributed Bio LLC in 2011, and incorporated to Distributed Bio Inc with Chris, Giles and Jake in 2012.

Andrew Hanneman, PhD
Scientific Advisor, Biologics Testing

Analysis of Polymeric Excipients and Process Residuals in AAV Gene Vector Products

Session Date/Time: Tuesday May 11, 2021 8:00 AM - 10:00 AM
Session Title: Vector Product Engineering, Development or Manufacturing
Room: Digital Gallery

Romain Genard
Scientist 2, IMM

Lentiviral Vector Use in Pre-Clinical Work for Gene and Cell Therapy Application - Method and FeasibilityHi

Session Date/Time: Tuesday May 11, 2021 8:00 AM - 10:00 AM
Session Title: RNA Virus Vectors
Room: Digital Gallery

Katherine Vousden PhD
Science Director, Large Molecules

End to End Discovery to Support the Development of Safe and Efficacious Engineered Cell Therapies

Session Date/Time: Tuesday May 11, 2021 8:00 AM - 10:00 AM
Session Title: Cancer - Targeted Gene and Cell Therapy
Room: Digital Gallery

Erik Larson,
Scientist 2, SD

Stereotactic Convection Enhanced Delivery Infusions Directed by Real Time MRI in NHP Models

Session Date/Time: Tuesday May 11, 2021 8:00 AM - 10:00 AM
Session Title: Pharmacology/Toxicology Studies or Assay Development
Room: Digital Gallery

Simon Authier
Sr Director Sci Ops VetSvc

Cell Therapy Assessments in the NCG Mouse Model: Study Design and Success Factors

Session Date/Time: Tuesday May 11, 2021 8:00 AM - 10:00 AM
Session Title: Pharmacology/Toxicology Studies or Assay Development
Room: Digital Gallery

Danielle L. Brown, DVM, MS, DACVP, DABT, FIATP
General Manager, Pathology Associates

Use of Transmission Electron Microscopy and Deep Learning for Classification of AAV Capsids

Session Date/Time: Tuesday May 11, 2021 8:00 AM - 10:00 AM
Session Title: AAV Vectors - Virology and Vectorology
Room: Digital Gallery

Sung Ryeol Park
Scientist 1, Methods Development

Utilizing a QF-PCR Platform to Detect Replication Competent Lentivirus and Product-Related Impurities in Gene and Cell Therapy Products

Session Date/Time: Tuesday May 11, 2021 8:00 AM - 10:00 AM
Session Title: Pharmacology/Toxicology Studies or Assay Development
Room: Digital Gallery

 

 

Charles River offers end-to-end development services for cell and gene therapy research. The Charles River cell and gene therapy research scientists present various presentations sharing insights on our services offered.

Cell and gene therapies are complex but developing them doesn’t have to be. WIth unique entities, part of the challenge is not knowing the next step to take. In these educational videos, our experts describe critical considerations, key strategies, and the technologies that can make your program a success.

Learn more